SORT BY

FILTER BY

also on other fortune lists

company facts

g500 stats

Global 500

Demond Meek

52

Express Scripts Holding

ESRX

U.S.

Over the past decade, Express Scripts has become the largest pharmacy benefit manager in the U.S. as the industry has consolidated. The company processes some 1.5 billion claims every year. The question now is if it can compete using its unique stand-alone business model with rivals like CVS Health that pursue a multi-pronged approach. Express Scripts has benefited from the wave of newly insured patients as a result of the Affordable Care Act and has significantly expanded its profit margins over the past five years, hitting 6.9% in 2015 compared to 5.4% in 2010. However, the company is at risk of losing its biggest customer. Express Scripts has been locked in a contract dispute with insurance giant Anthem, which accused Express Scripts of breach of contract and requested damages of as much as $13 billion. Anthem accounted for about 16% of Express Scripts’ revenue in 2015, and the likelihood of a contract renewal by 2019 is at stake.

CEO

Timothy C. Wentworth

Sector

Health Care

Industry

Miscellaneous

HQ Location

St. Louis, MO

Employees

25,900

Years on Global 500 List

14

Key Financials (last fiscal year)
($ Millions)% change
Revenues ($M)$101,7520.9%
Profits ($M)$2,47623.4%
Assets ($M)$53,243
Total Stockholder Equity ($M)$17,373
Profit Ratios
Profit as % of Revenues2.4%
Profits as % of Assets4.7%
Profits as % of Stockholder Equity14.3%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Express Scripts Holding

PBMs Are Hogging Our Drug Discounts

Kudos to Trump for taking them on.

Read More →
What Carl Icahn Said In His Brutal Letter Slamming the Cigna-Express Scripts Deal

Icahn isn't mincing words, urging Cigna shareholders to reject the $60 billion proposed deal.

Read More →
Why Trump's Big Drug Price Speech Sent Health Care Stocks Soaring

The president's drug price proposals didn't shake big pharma and other health care companies.

Read More →